Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28
- 1 August 2010
- Vol. 28 (35) , 5691-5702
- https://doi.org/10.1016/j.vaccine.2010.06.050
Abstract
No abstract availableKeywords
Funding Information
- NIH SBIR (R43 AI062176-01A1)
This publication has 65 references indexed in Scilit:
- An Arginine Switch in the Species B Adenovirus Knob Determines High-Affinity Engagement of Cellular Receptor CD46Journal of Virology, 2009
- HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisThe Lancet, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialPublished by Elsevier ,2008
- Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeysNature, 2008
- Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus MonkeysJournal of Virology, 2008
- TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccinesNature, 2008
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and DJournal of Virology, 2007
- Sensing Infection by Adenovirus: Toll-Like Receptor-Independent Viral DNA Recognition Signals Activation of the Interferon Regulatory Factor 3 Master RegulatorJournal of Virology, 2007
- Preferential Activation of Toll-Like Receptor Nine by CD46-Utilizing AdenovirusesJournal of Virology, 2007
- Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41Vaccine, 2006